预约演示

更新于：2025-05-07

α-synuclein

更新于：2025-05-07

基本信息

别名

Alpha-synuclein、NACP、non A4 component of amyloid precursor

+ [11]

简介

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release (PubMed:20798282, PubMed:26442590, PubMed:28288128, PubMed:30404828). Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed:28288128, PubMed:30404828). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis (PubMed:30404828). Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed:20798282). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed:20798282). Also plays a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed:26442590).

关联

140

项与 α-synuclein 相关的药物

Ethambutol Hydrochloride/Rifampicin/Isoniazid

盐酸乙胺丁醇/利福平/异烟肼

靶点

Bacterial RNAP x α-synuclein

作用机制

Bacterial RNAP抑制剂 [+1]

在研机构

沈阳红旗制药有限公司

原研机构

沈阳红旗制药有限公司

在研适应症

结核

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2008-03-03

Amlenetug

靶点

α-synuclein

作用机制

α-synuclein抑制剂

在研机构

H. Lundbeck A/S [+2]

原研机构

Genmab A/S [+1]

在研适应症

多系统萎缩 [+1]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

Indenebart

靶点

α-synuclein

作用机制

α-synuclein抑制剂

在研机构

Takeda Pharmaceutical Co., Ltd. [+1]

原研机构

AstraZeneca PLC

在研适应症

多系统萎缩 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

148

项与 α-synuclein 相关的临床试验

CTRI/2025/04/085327

/ Not yet recruiting临床4期IIT

One-year Comparative evaluation of effect of emblica officinalis, Epigallactocatechin-3-gallate, chlorhexidine using selective etch technique on clinical performance of composite resin restoration in cases of Non carious cervical lesions: A randomized clinical study - NIL

开始日期2025-05-15

申办/合作机构-

TCTR20250317007

/ Not yet recruiting临床1期IIT

Skin Evaluation of Turmeric/EGCG Emulgel for Skin Irritation and Sensitization Effects in Healthy Participants

开始日期2025-05-01

申办/合作机构

Chiang Mai University

CTRI/2025/03/082145

/ Not yet recruiting临床2期IIT

Comparative Evaluation Of Indirect Pulp Therapy In Young Permanent Teeth Using Nanohydroxyapatite And Epigallocatechin-3-Gallate (EGCG) Mix Versus Biodentine: A Randomized Controlled Trial - NIL

开始日期2025-04-27

申办/合作机构-

100 项与 α-synuclein 相关的临床结果

登录后查看更多信息

100 项与 α-synuclein 相关的转化医学

登录后查看更多信息

0 项与 α-synuclein 相关的专利（医药）

登录后查看更多信息

25,805

项与 α-synuclein 相关的文献（医药）

2026-01-01·Neural Regeneration Research

Targeting the glymphatic system to promote α-synuclein clearance: a novel therapeutic strategy for Parkinson’s disease

Article

作者: Liu, Zhenghao ; Chen, Jiang-fan ; Lian, Xiaoyue ; Tong, Luyao ; Gan, Zuobin ; Liu, Yuntao ; Li, Zhihui ; Yan, Qingshan ; Qiu, Linan

The excessive buildup of neurotoxic α-synuclein plays a pivotal role in the pathogenesis of Parkinson’s disease, highlighting the urgent need for innovative therapeutic strategies to promote α-synuclein clearance, particularly given the current lack of disease-modifying treatments. The glymphatic system, a recently identified perivascular fluid transport network, is crucial for clearing neurotoxic proteins. This review aims to synthesize current knowledge on the role of the glymphatic system in α-synuclein clearance and its implications for the pathology of Parkinson’s disease while emphasizing potential therapeutic strategies and areas for future research. The review begins with an overview of the glymphatic system and details its anatomical structure and physiological functions that facilitate cerebrospinal fluid circulation and waste clearance. It summarizes emerging evidence from neuroimaging and experimental studies that highlight the close correlation between the glymphatic system and clinical symptom severity in patients with Parkinson’s disease, as well as the effect of glymphatic dysfunction on α-synuclein accumulation in Parkinson’s disease models. Subsequently, the review summarizes the mechanisms of glymphatic system impairment in Parkinson’s disease, including sleep disturbances, aquaporin-4 impairment, and mitochondrial dysfunction, all of which diminish glymphatic system efficiency. This creates a vicious cycle that exacerbates α-synuclein accumulation and worsens Parkinson’s disease. The therapeutic perspectives section outlines strategies for enhancing glymphatic activity, such as improving sleep quality and pharmacologically targeting aquaporin-4 or its subcellular localization. Promising interventions include deep brain stimulation, melatonin supplementation, γ-aminobutyric acid modulation, and non-invasive methods (such as exercise and bright-light therapy), multisensory γ stimulation, and ultrasound therapy. Moreover, identifying neuroimaging biomarkers to assess glymphatic flow as an indicator of α-synuclein burden could refine Parkinson’s disease diagnosis and track disease progression. In conclusion, the review highlights the critical role of the glymphatic system in α-synuclein clearance and its potential as a therapeutic target in Parkinson’s disease. It advocates for further research to elucidate the specific mechanisms by which the glymphatic system clears misfolded α-synuclein and the development of imaging biomarkers to monitor glymphatic activity in patients with Parkinson’s disease. Findings from this review suggest that enhancing glymphatic clearance is a promising strategy for reducing α-synuclein deposits and mitigating the progression of Parkinson’s disease.

2026-01-01·Neural Regeneration Research

Alpha-synuclein-induced upregulation of SKI family transcriptional corepressor 1: A new player in aging and Parkinson’s disease?

Article

作者: Collins, Louise M. ; Barrett, Lauren ; Bevans, Rebekah ; O’Keeffe, Gerard W. ; Sullivan, Aideen M.

2026-01-01·Neural Regeneration Research

Hidden face of Parkinson’s disease: Is it a new autoimmune disease?

Article

作者: Kim, Seon-Hee ; Jo, Min Gi ; Yun, Seung Pil

Parkinson’s disease is a neurodegenerative disorder marked by the degeneration of dopaminergic neurons and clinical symptoms such as tremors, rigidity, and slowed movements. A key feature of Parkinson’s disease is the accumulation of misfolded α-synuclein, forming insoluble Lewy bodies in the substantia nigra pars compacta, which contributes to neurodegeneration. These α-synuclein aggregates may act as autoantigens, leading to T-cell-mediated neuroinflammation and contributing to dopaminergic cell death. Our perspective explores the hypothesis that Parkinson’s disease may have an autoimmune component, highlighting research that connects peripheral immune responses with neurodegeneration. T cells derived from Parkinson’s disease patients appear to have the potential to initiate an autoimmune response against α-synuclein and its modified peptides, possibly leading to the formation of neo-epitopes. Recent evidence associates Parkinson’s disease with abnormal immune responses, as indicated by increased levels of immune cells, such as CD4+ and CD8+ T cells, observed in both patients and mouse models. The convergence of T cells filtration increasing major histocompatibility complex molecules, and the susceptibility of dopaminergic neurons supports the hypothesis that Parkinson’s disease may exhibit autoimmune characteristics. Understanding the immune mechanisms involved in Parkinson’s disease will be crucial for developing therapeutic strategies that target the autoimmune aspects of the disease. Novel approaches, including precision medicine based on major histocompatibility complex/human leukocyte antigen typing and early biomarker identification, could pave the way for immune-based treatments aimed at slowing or halting disease progression. This perspective explores the relationship between autoimmunity and Parkinson’s disease, suggesting that further research could deepen understanding and offer new therapeutic avenues. In this paper, it is organized to provide a comprehensive perspective on the autoimmune aspects of Parkinson’s disease. It investigates critical areas such as the autoimmune response observed in Parkinson’s disease patients and the role of autoimmune mechanisms targeting α-synuclein in Parkinson’s disease. The paper also examines the impact of CD4+ T cells, specifically Th1 and Th17, on neurons through in vitro and ex vivo studies. Additionally, it explores how α-synuclein influences glia-induced neuroinflammation in Parkinson’s disease. The discussion extends to the clinical implications and therapeutic landscape, offering insights into potential treatments. Consequently, we aim to provide a comprehensive perspective on the autoimmune aspects of Parkinson’s disease, incorporating both supportive and opposing views on its classification as an autoimmune disorder and exploring implications for clinical applications.

704

项与 α-synuclein 相关的新闻（医药）

2025-05-01

·梅斯医学

早诊帕金森，看血就够了？Nature Aging：血液中这几种蛋白，竟可预测疾病进展

帕金森病（PD）是一种常见的神经退行性疾病，其主要病理特征包括运动功能障碍、认知功能下降和自主神经功能障碍等。尽管近年来在PD的研究中取得了一些进展，但目前仍缺乏有效的生物标志物用于早期诊断和疾病进展监测。蛋白质组学作为一种 powerful 的研究工具，能够提供关于疾病发生发展过程中蛋白质表达变化的详细信息，为揭示PD的病理机制和发现新的生物标志物提供了可能。近期，Nature Aging杂志上发表的一项研究通过大规模蛋白质组学分析，为帕金森病（PD）的发病机制和生物标志物研究提供了新的视角。这项研究不仅揭示了PD的新病理机制，还发现了多个潜在的生物标志物，为早期诊断和治疗提供了新的方向。研究团队利用大规模蛋白质组学分析技术，对来自英国生物样本库（UK Biobank，UKB）和帕金森进展标志物倡议（PPMI）数据库的样本进行了深入研究。这些样本涵盖了PD患者和健康对照组，研究涉及了多种蛋白质的定量分析，通过蛋白质组学技术，研究人员能够系统地评估PD患者血液和大脑组织中的蛋白质表达变化。研究团队在UKB和PPMI数据库中获取了丰富的临床和遗传信息，这些数据为研究提供了坚实的基础。通过蛋白质组学分析，研究人员能够识别出与PD相关的蛋白质表达变化，并进一步探讨这些变化与疾病进展之间的关系。研究结果表明，PD患者血液和大脑组织中多种蛋白质的表达水平发生了显著变化。这些蛋白质涉及多个生物学过程，包括神经传递、细胞骨架稳定、氧化应激反应和免疫调节等。其中，一些蛋白质的表达变化与疾病的严重程度和进展速度密切相关，提示它们可能作为潜在的生物标志物用于PD的早期诊断和疾病监测。研究人员发现，与健康对照组相比，PD患者血液中的α-突触核蛋白（α-synuclein）水平显著升高。这一发现与以往的研究结果一致，进一步证实了α-synuclein在PD病理过程中的关键作用。此外，研究还发现了一些新的蛋白质标志物，如神经丝轻链（NfL）、胶质纤维酸性蛋白（GFAP）和髓鞘碱性蛋白（MBP）等，这些蛋白质的表达变化与PD的病理特征密切相关。这项研究的发现对于PD的诊断和治疗具有重要意义。首先，研究揭示了PD新的病理机制，为开发新型治疗策略提供了理论基础。其次，研究发现了多个潜在的生物标志物，这些标志物有望用于PD的早期诊断和疾病进展监测，从而提高治疗效果和患者生活质量。最后，研究还强调了蛋白质组学技术在神经退行性疾病研究中的重要性，为未来的研究提供了新的思路和方法。综上所述，这项研究通过大规模蛋白质组学分析，揭示了PD的新病理机制，并发现了多个潜在的生物标志物。这些发现不仅增进了我们对PD发病机制的理解，还为开发新的诊断工具和治疗策略提供了重要的线索。未来的研究可以进一步验证这些生物标志物的临床应用价值，并探索它们在疾病早期阶段的检测潜力。通过这些努力，我们有望为PD患者提供更精准的诊断和更有效的治疗方案。参考资料：[1]Large-scale proteomic analyses of incident Parkinson's disease reveal new pathophysiological insights and potential biomarkers. Nat Aging. 2025 Apr;5(4):642-657. doi: 10.1038/s43587-025-00818-0. Epub 2025 Feb 20. PMID: 39979637.撰文 | 梅斯医学编辑 | 木白● 教训！广东大三甲出现低级错误！患者手术成功，全麻苏醒过程中缺氧30分钟，导致脑死亡！麻醉无小事，近期出现两起生殖微创术后死亡事件● 延寿7-8年，护肝，减重又抗癌！三登顶刊：饮料中这种常见成分还能减轻肝损伤，延缓衰老● 读了985临床七年制，就业咋那么难！去县城事业编 or 新疆大医院？北京四中家长：读临床7年制很后悔，只是硕士，毕业还得规培版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

2025-05-01

·PRNewswire

CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics

Latest Series A3 financing includes Labcorp, along with new and longtime investors SCOTTSDALE, Ariz., May 1, 2025 /PRNewswire/ -- CND Life Sciences, Inc. (CND) announced today that it has raised $13.5 million in its Series A equity financing round, with $8.6 million in its most recent Series A3 offering. The company's strong growth has been fueled by its innovative Syn-One Test® that uses skin biopsy tissue to detect and quantify the abnormal form of the alpha-synuclein protein, a known pathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy and other related disorders. Continue Reading CND Life Sciences closes $13.5M Series A equity financing round to continue neurodiagnostics growth and innovation. Post this (PRNewsfoto/CND Life Sciences) "This is a defining time for the neurodegeneration field," said Richard J. Morello, CND's chief executive officer. "CND uses proven technology to help clinicians diagnose diseases like Parkinson's earlier and more precisely than ever before, while collaborating with biopharmaceutical companies to improve the chances for successful clinical trials for novel therapies. We are grateful for the significant support of our mission by many dedicated investors." CND launched its Syn-One Test in late 2019, which has been used by nearly 3,000 neurologists and other clinicians to aid in the diagnosis of synuclein-associated disorders like PD for more than 35,000 patients. In 2024, CND published a key study in the Journal of the American Medical Association demonstrating Syn-One's 95.5% sensitivity overall in detecting abnormal synuclein in patients with different synuclein-associated diseases. Additionally, Syn-One Biomarker Technology™, which leverages CND's AI-assisted platform NerValence™ to quantify the amount of synuclein detected in cutaneous nerves, is being applied in multiple pharmaceutical clinical trials with the hope of measuring an investigational drug's effect on the pathological protein. "Without accurate diagnosis and objective measures of disease progression and therapy response, treatment of the synuclein-related disorders will be hampered," said Christopher Gibbons, MD, chief scientific officer of CND. "Using our proprietary technology, we are able to support a more precise diagnosis and provide convenient, reproducible measures of disease progression and severity in PD, DLB and other synucleinopathies. These advancements offer real opportunities to deliver more effective patient care and accelerate development of disease-modifying therapies." CND's latest Series A3 round included funding from existing investor groups Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital and BlueStone Ventures and from new investors Labcorp, a global leader of innovative and comprehensive laboratory services, MBX Capital and Vilas Ventures. "We are excited to support CND's mission to scale access to their Syn-One Test as part of our deep commitment to help deliver innovative neurology tests and treatments," said Megann Vaughn Watters, Labcorp's vice president of New Ventures & Strategic Alliances. "We are encouraged by the strong adoption of CND's innovative testing that is providing actionable information to ordering clinicians and closing gaps in care for patients facing neurodegenerative diseases." About CND Life Sciences CND Life Sciences supports the care of patients facing the potential diagnosis of neurodegenerative disease and other neurological conditions. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, CND developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure and REM sleep behavior disorder. Syn-One uses proprietary immunofluorescence techniques to detect, visualize and quantify phosphorylated alpha-synuclein in cutaneous nerves. Results of a prospective, multicenter NIH-sponsored study of the Syn-One Test were published in the Journal of the American Medical Association (JAMA) in 2024 demonstrating >95% sensitivity overall in patients with a clinically determined synucleinopathy.1 The test analyzes three small skin biopsy samples collected in a clinician's office through an in-office patient procedure and includes an assessment of intraepidermal nerve fiber density and other important pathologic markers. Nearly 3,000 neurologists and other clinicians in 50 states have used the Syn-One Test to support their diagnostic evaluation of patients. The company also collaborates with biopharmaceutical companies on clinical trials for investigational therapies targeting neurodegenerative diseases and is conducting studies assessing the test's ability to provide early disease detection and prognostic insights. For more information, visit cndlifesciences.com or connect with us on LinkedIn. 1Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792. Media Contact: Jaryd Leady (856) 803-7855 [email protected] Company Contact: Kathryn Van Wie SVP, Commercial Strategy & Market Development [email protected] SOURCE CND Life Sciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

2025-04-30

·PRNewswire

XingImaging Unveils NX PET Camera to Advance Parkinson's Disease Research

NEW HAVEN, Conn., April 30, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a pioneer in advanced research imaging, radiopharmaceutical services, and medical imaging technology, proudly announces the launch of the **NX PET Camera**, a breakthrough in positron emission tomography (PET) imaging designed to accelerate research into critical biomarkers for Parkinson's disease. The **NX PET Camera** offers cutting-edge imaging capabilities, providing researchers with unparalleled precision in detecting and tracking neurodegenerative biomarkers. With **high-resolution PET imaging**, **advanced AI-driven data analysis**, and **enhanced biomarker mapping**, the NX PET Camera is set to revolutionize the study of Parkinson's disease progression and therapeutic response. "Early and accurate biomarker detection is key to advancing our understanding and treatment of Parkinson's disease," said Gilles Tamagnan, CEO of XingImaging. "The NX PET Camera delivers the next-generation imaging technology needed to support groundbreaking research and improve patient outcomes." The Michael J. Fox Foundation for Parkinson's Research (MJFF) funded XingImaging researchers with an aim to use PET imaging to visualize changes in the dopamine pathway of the brain to collect data about PD. Jamie Eberling, PhD, senior vice president of research resources at MJFF, said of the camera's launch, "There's been monumental progress in the last few years through strong investments in finding tracers that can show us alpha-synuclein and other targets in the living brain. This high-resolution PET imaging technology magnifies the impact of these tracers by improving what we can see in real-time. The field is energized by the latest milestones in imaging getting us closer to a day where we can clearly measure, quantify and visualize brain pathology in Parkinson's disease." The NeuroExplorer PET camera from United Imaging is a next-generation ultra-high performance human brain PET imager scanner offering unparalleled resolution (1.4 mm FWHM) and sensitivity (46 kcps/MBq) in the study of brain function. This promises to be revolutionary for imaging of neurodegenerative diseases, like Parkinson's & Alzheimer's, and psychiatric diseases enabling high signal to noise imaging even for small brain structures. XingImaging's NeuroExplorer PET camera enhances the company's delivery of the highest quality science for its research and drug development partners. Key Features of the NX PET Camera: **Ultra-High-Resolution Imaging**: Enables precise visualization of neurodegenerative biomarkers. **AI-Powered Data Analysis**: Advanced machine learning algorithms enhance image interpretation and diagnostic accuracy. **Dynamic Biomarker Mapping**: Provides real-time insights into brain activity and disease progression. **Non-Invasive & Efficient**: Minimizes patient discomfort while delivering rapid, high-quality results. About XingImaging XingImaging is a pioneer in medical imaging technology, committed to advancing healthcare research through innovative solutions. By developing state-of-the-art imaging systems, the company supports researchers and clinicians in their mission to improve XingImaging, a subsidiary of MITRO, is a leading provider of advanced research imaging and radiopharmaceutical services. With a firm focus on quality and innovation, the company offers comprehensive clinical trial imaging services, core lab services, and radiotracer manufacturing. By maintaining the highest industry standards, XingImaging partners with research pharmaceutical and biotech organizations to drive breakthroughs in medical diagnostics and treatment diagnostic accuracy and therapeutic outcomes for neurological diseases. About MITRO MITRO is a molecular imaging contract research organization (MI-CRO) company in China. MITRO provides outstanding contract research for new drug development using radiolabeling and molecular imaging techniques. MITRO merged with XingImaging in 2023 to create one company dedicated to providing a full spectrum of CRO & CDMO research service offerings. New Haven Facility Our New Haven facility offers a comprehensive range of services, including: Clinical Trial Services: State-of-the-art Clinic providing consistent, compassionate, and high-quality services to research participants to support clinical trials. Advanced Imaging Services: Advanced imaging technologies designed and implemented with an emphasis on precision and quality, including PET and SPECT. Radiotracer Manufacturing: Tailored GMP production to meet the precise needs of clinical trials with stringent quality control. Leading Imaging Analysis Services: Tailored analysis pipelines that focus on maximizing signal-to-noise, robustness and reproducibility. XingImaging's commitment to excellence is reflected in every aspect of the new facility's operations, ensuring that participants, sponsors, and collaborators receive the highest quality of service. The NX PET Camera is now available for research institutions, hospitals, and pharmaceutical partners aiming to accelerate biomarker discovery and drug development for Parkinson's disease and other neurodegenerative disorders. SOURCE XingImaging, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED